Page 4 - புற்றுநோய் ப்ரெவெந்ஶந் ஆராய்ச்சி நிறுவனம் ஆஃப் டெக்சாஸ் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from புற்றுநோய் ப்ரெவெந்ஶந் ஆராய்ச்சி நிறுவனம் ஆஃப் டெக்சாஸ். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In புற்றுநோய் ப்ரெவெந்ஶந் ஆராய்ச்சி நிறுவனம் ஆஃப் டெக்சாஸ் Today - Breaking & Trending Today

Novel guidelines help select optimal deconvolution method


Date Time
Novel guidelines help select optimal deconvolution method
Biomedical scientists are increasingly using deconvolution methods, those used to computationally analyze the composition of complex mixtures of cells. One of their challenges is to select one method that is appropriate for their experimental conditions among nearly 50 available.
To help with method selection, researchers at Baylor College of Medicine and the Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital have extensively evaluated 11 deconvolution methods that are based on RNA-sequencing (RNA-seq) data analysis, determining each method’s individual strengths and weaknesses in a variety of scenarios. From these analyses, the researchers derived guidelines that scientists can use to determine the deconvolution method that optimally fits their needs. The study appears in the journal Genome Biology. ....

United States , Baylor College Of Medicine , Haijing Jin , Zhandong Liu , Chao Family Foundation , Dan Duncan Neurological Research Institute , Huffington Foundation , National Institute , Cancer Prevention Research Institute Of Texas , Baylor College , Texas Children , Bioinformatics Core , Dan Duncan Neurological Research , General Medical Sciences , Cancer Prevention Research Institute , Houston Endowment , ஒன்றுபட்டது மாநிலங்களில் , பேலர் கல்லூரி ஆஃப் மருந்து , குழப்பம் குடும்பம் அடித்தளம் , டான் டங்கன் நரம்பியல் ஆராய்ச்சி நிறுவனம் , ஹஃபிங்டன் அடித்தளம் , தேசிய நிறுவனம் , புற்றுநோய் ப்ரெவெந்ஶந் ஆராய்ச்சி நிறுவனம் ஆஃப் டெக்சாஸ் , பேலர் கல்லூரி , டெக்சாஸ் குழந்தைகள் , உயிர் தகவலியல் கோர் ,

Iterion Therapeutics Confirms Safety of Tegavivint Following Completion of Enrollment in Phase 1/2a Expansion Study in Patients with Desmoid Tumors


Iterion Therapeutics Confirms Safety of Tegavivint Following Completion of Enrollment in Phase 1/2a Expansion Study in Patients with Desmoid Tumors
Data provides springboard to advance three additional clinical programs evaluating Tegavivint in acute myeloid leukemia (AML), non-small cell lung cancer (NSCLC) and pediatric cancers
News provided by
Share this article
Share this article
HOUSTON, April 13, 2021 /PRNewswire/ Iterion Therapeutics, Inc., a venture-backed, clinical stage biotechnology company developing novel cancer therapeutics, announced today that it has confirmed the safety of Tegavivint, a novel, potent and selective nuclear beta-catenin inhibitor, after completing enrollment and dosing the final patient in a multicenter Phase 1/2a dose expansion clinical study of Tegavivint in patients with desmoid tumors.  ....

United States , Casey Cunningham , Tiberend Strategic Advisors Inc , Cancer Prevention Research Institute Of Texas , Prnewswire Iterion Therapeutics Inc , Transducin Beta Like Protein One , Chief Medical Officer , Orphan Drug Designation , Cancer Prevention , Research Institute , Strategic Advisors , Ingrid Mezo , Iterion Therapeutics , ஒன்றுபட்டது மாநிலங்களில் , வழக்கு கன்னிங்ஹாம் , புற்றுநோய் ப்ரெவெந்ஶந் ஆராய்ச்சி நிறுவனம் ஆஃப் டெக்சாஸ் , தலைமை மருத்துவ அதிகாரி , ஆர்ஃபந் மருந்து பதவி , புற்றுநோய் ப்ரெவெந்ஶந் , ஆராய்ச்சி நிறுவனம் ,

Mutant KRAS and p53 cooperate to drive pancreatic cancer metastasis


Date Time
Mutant KRAS and p53 cooperate to drive pancreatic cancer metastasis
Researchers at The University of Texas MD Anderson Cancer Center have discovered that mutant KRAS and p53, the most frequently mutated genes in pancreatic cancer, interact through the CREB1 protein to promote metastasis and tumor growth. Blocking CREB1 in preclinical models reversed these effects and reduced metastases, suggesting an important new therapeutic target for the deadly cancer.
“To our knowledge, this is the first study to show how these two major genetic drivers work together to promote tumor growth and metastasis,” Kim said. “We learned that signaling downstream of mutant KRAS directly promotes mutant p53 activity. This discovery provides not only a new therapeutic target but unveils a vast transcriptional network that is activated downstream of these mutant proteins.” ....

United States , Bingbing Dai , Gigi Lozano , Amandar Wasylishen , Jithesh Augustine , Jasonb Fleming , Yaan Kang , Timothyp Heffernan , Florencia Mcallister , Michael Kim , Christopher Bristow , Kendra Allton , Shunbin Xiong , Jenying Deng , Eugene Koay , Yun Zhang , Tarag Hughes , Michellec Barton , Guillermina Lozano , Christian Siangco , Xinqun Li , Anirban Maitra , Sheikh Ahmed Bin Zayed Al Nahyan Center , University Of Texas Md Anderson Cancer Center , National Institutes Of Health , Rose Cole Charitable Pria Foundation ,